A Multicenter, Randomized, Double-Blind, Placebo-Controlled 12-Week Phase II Proof of Concept Study to Evaluate the Efficacy and Safety of PRC-4016 Once Daily Versus Placebo in Statin-Naïve or Statin-Stable Hypertriglyceridemic Subjects

Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled 12-Week Phase II Proof of Concept Study to Evaluate the Efficacy and Safety of PRC-4016 Once Daily Versus Placebo in Statin-Naïve or Statin-Stable Hypertriglyceridemic Subjects

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Nov 2015

At a glance

  • Drugs Icosabutate (Primary)
  • Indications Hypertriglyceridaemia
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Pronova BioPharma
  • Most Recent Events

    • 25 May 2015 According to a BASF media release, data from this study were presented at the 17th International Symposium on Atherosclerosis (ISA).
    • 25 May 2015 Results published in a BASF media release.
    • 25 May 2015 Primary endpoint has been met (Percent change in triglycerides from baseline to week 12) according to a BASF media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top